Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction

Background Liver fibrosis is a common outcome of chronic liver disease and is primarily driven by hepatic stellate cell (HSC) activation. Irisin, a myokine released during physical exercise, is beneficial for metabolic disorders and mitochondrial dysfunction. This study aimed to explore the effects...

Full description

Saved in:
Bibliographic Details
Main Authors: Thuy Linh Lai, So Young Park, Giang Nguyen, Phuc Thi Minh Pham, Seon Mee Kang, Jeana Hong, Jae-Ho Lee, Seung-Soon Im, Dae-Hee Choi, Eun-Hee Cho
Format: Article
Language:English
Published: Korean Endocrine Society 2024-12-01
Series:Endocrinology and Metabolism
Subjects:
Online Access:http://www.e-enm.org/upload/pdf/enm-2024-1984.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1841561187670556672
author Thuy Linh Lai
So Young Park
Giang Nguyen
Phuc Thi Minh Pham
Seon Mee Kang
Jeana Hong
Jae-Ho Lee
Seung-Soon Im
Dae-Hee Choi
Eun-Hee Cho
author_facet Thuy Linh Lai
So Young Park
Giang Nguyen
Phuc Thi Minh Pham
Seon Mee Kang
Jeana Hong
Jae-Ho Lee
Seung-Soon Im
Dae-Hee Choi
Eun-Hee Cho
author_sort Thuy Linh Lai
collection DOAJ
description Background Liver fibrosis is a common outcome of chronic liver disease and is primarily driven by hepatic stellate cell (HSC) activation. Irisin, a myokine released during physical exercise, is beneficial for metabolic disorders and mitochondrial dysfunction. This study aimed to explore the effects of irisin on liver fibrosis in HSCs, a bile duct ligation (BDL) mouse model, and the associated mitochondrial dysfunction. Methods In vitro experiments utilized LX-2 cells, a human HSC line, stimulated with transforming growth factor-β1 (TGF-β1), a major regulator of HSC fibrosis, with or without irisin. Mitochondrial function was assessed using mitochondrial fission markers, transmission electron microscopy, mitochondrial membrane potential, and adenosine triphosphate (ATP) production. In vivo, liver fibrosis was induced in mice via BDL, followed by daily intraperitoneal injections of irisin (100 μg/kg/day) for 10 days. Results In vitro, irisin mitigated HSC activation and reduced reactive oxygen species associated with the TGF-β1/Smad signaling pathway. Irisin restored TGF-β1-induced increases in fission markers (Fis1, p-DRP1) and reversed the decreased expression of TFAM and SIRT3. Additionally, irisin restored mitochondrial membrane potential and ATP production lowered by TGF-β1 treatment. In vivo, irisin ameliorated the elevated liver-to-body weight ratio induced by BDL and alleviated liver fibrosis, as evidenced by Masson’s trichrome staining. Irisin also improved mitochondrial dysfunction induced by BDL surgery. Conclusion Irisin effectively attenuated HSC activation, ameliorated liver fibrosis in BDL mice, and improved associated mitochondrial dysfunction. These findings highlight the therapeutic potential of irisin for the treatment of liver fibrosis.
format Article
id doaj-art-65b4d63af43b44f0b59ab7a784899f2f
institution Kabale University
issn 2093-596X
2093-5978
language English
publishDate 2024-12-01
publisher Korean Endocrine Society
record_format Article
series Endocrinology and Metabolism
spelling doaj-art-65b4d63af43b44f0b59ab7a784899f2f2025-01-03T05:15:26ZengKorean Endocrine SocietyEndocrinology and Metabolism2093-596X2093-59782024-12-0139690892010.3803/EnM.2024.19842543Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial DysfunctionThuy Linh Lai0So Young Park1Giang Nguyen2Phuc Thi Minh Pham3Seon Mee Kang4Jeana Hong5Jae-Ho Lee6Seung-Soon Im7Dae-Hee Choi8Eun-Hee Cho9 Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea Department of Pediatrics, Kangwon National University School of Medicine, Chuncheon, Korea Department of Physiology, Keimyung University School of Medicine, Daegu, Korea Department of Physiology, Keimyung University School of Medicine, Daegu, Korea Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, KoreaBackground Liver fibrosis is a common outcome of chronic liver disease and is primarily driven by hepatic stellate cell (HSC) activation. Irisin, a myokine released during physical exercise, is beneficial for metabolic disorders and mitochondrial dysfunction. This study aimed to explore the effects of irisin on liver fibrosis in HSCs, a bile duct ligation (BDL) mouse model, and the associated mitochondrial dysfunction. Methods In vitro experiments utilized LX-2 cells, a human HSC line, stimulated with transforming growth factor-β1 (TGF-β1), a major regulator of HSC fibrosis, with or without irisin. Mitochondrial function was assessed using mitochondrial fission markers, transmission electron microscopy, mitochondrial membrane potential, and adenosine triphosphate (ATP) production. In vivo, liver fibrosis was induced in mice via BDL, followed by daily intraperitoneal injections of irisin (100 μg/kg/day) for 10 days. Results In vitro, irisin mitigated HSC activation and reduced reactive oxygen species associated with the TGF-β1/Smad signaling pathway. Irisin restored TGF-β1-induced increases in fission markers (Fis1, p-DRP1) and reversed the decreased expression of TFAM and SIRT3. Additionally, irisin restored mitochondrial membrane potential and ATP production lowered by TGF-β1 treatment. In vivo, irisin ameliorated the elevated liver-to-body weight ratio induced by BDL and alleviated liver fibrosis, as evidenced by Masson’s trichrome staining. Irisin also improved mitochondrial dysfunction induced by BDL surgery. Conclusion Irisin effectively attenuated HSC activation, ameliorated liver fibrosis in BDL mice, and improved associated mitochondrial dysfunction. These findings highlight the therapeutic potential of irisin for the treatment of liver fibrosis.http://www.e-enm.org/upload/pdf/enm-2024-1984.pdfliver cirrhosisirisinhepatic stellate cellsmitochondriatransforming growth factor beta1
spellingShingle Thuy Linh Lai
So Young Park
Giang Nguyen
Phuc Thi Minh Pham
Seon Mee Kang
Jeana Hong
Jae-Ho Lee
Seung-Soon Im
Dae-Hee Choi
Eun-Hee Cho
Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction
Endocrinology and Metabolism
liver cirrhosis
irisin
hepatic stellate cells
mitochondria
transforming growth factor beta1
title Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction
title_full Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction
title_fullStr Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction
title_full_unstemmed Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction
title_short Irisin Attenuates Hepatic Stellate Cell Activation and Liver Fibrosis in Bile Duct Ligation Mice Model and Improves Mitochondrial Dysfunction
title_sort irisin attenuates hepatic stellate cell activation and liver fibrosis in bile duct ligation mice model and improves mitochondrial dysfunction
topic liver cirrhosis
irisin
hepatic stellate cells
mitochondria
transforming growth factor beta1
url http://www.e-enm.org/upload/pdf/enm-2024-1984.pdf
work_keys_str_mv AT thuylinhlai irisinattenuateshepaticstellatecellactivationandliverfibrosisinbileductligationmicemodelandimprovesmitochondrialdysfunction
AT soyoungpark irisinattenuateshepaticstellatecellactivationandliverfibrosisinbileductligationmicemodelandimprovesmitochondrialdysfunction
AT giangnguyen irisinattenuateshepaticstellatecellactivationandliverfibrosisinbileductligationmicemodelandimprovesmitochondrialdysfunction
AT phucthiminhpham irisinattenuateshepaticstellatecellactivationandliverfibrosisinbileductligationmicemodelandimprovesmitochondrialdysfunction
AT seonmeekang irisinattenuateshepaticstellatecellactivationandliverfibrosisinbileductligationmicemodelandimprovesmitochondrialdysfunction
AT jeanahong irisinattenuateshepaticstellatecellactivationandliverfibrosisinbileductligationmicemodelandimprovesmitochondrialdysfunction
AT jaeholee irisinattenuateshepaticstellatecellactivationandliverfibrosisinbileductligationmicemodelandimprovesmitochondrialdysfunction
AT seungsoonim irisinattenuateshepaticstellatecellactivationandliverfibrosisinbileductligationmicemodelandimprovesmitochondrialdysfunction
AT daeheechoi irisinattenuateshepaticstellatecellactivationandliverfibrosisinbileductligationmicemodelandimprovesmitochondrialdysfunction
AT eunheecho irisinattenuateshepaticstellatecellactivationandliverfibrosisinbileductligationmicemodelandimprovesmitochondrialdysfunction